DOI QR코드

DOI QR Code

In Vitro Study of Transdermal Delivery System for Caffein in Slim Patch Type

Slim Patch Type을 이용한 카페인의 경피흡수에 관한 연구

  • Published : 2006.04.20

Abstract

The aim of this study was to investigate the feasibility and optimize permeability of slim patch type as a transdermal delivery system of caffein. Slim patch type was formulated and tested in modified Franz diffusion cell across cellulose membrane and hairless mouse skin in pH 5.8 phosphate buffer solution (PBS). The effect of $Pharmsolv^{\circledR}$ and drug concentration on permeation at four model, 1,2% $Pharmsolv^{\circledR}$ with $0.12\;mg/cm^2$ caffein and 0.12, $1.2\;mg/cm^2$ caffein with 2% $Pharmsolv^{\circledR}$ through hairless mouse skin was studied in vitro. The release of caffein from slim patch with various loading was fitted by the Higuchi's diffusion equation. The result showed that chemical $Pharmsolv^{\circledR}$ produced a large and significant increase of permeation. The effect of 2% $Pharmsolv^{\circledR}$ on permeation of caffein was greater about 10-fold greater than 1% $Pharmsolv^{\circledR}$ in first 60 minutes. The effect of drug concentration, however, was lower than that produced by chemical $Pharmsolv^{\circledR}$. Within the tested system, the most efficient combination for caffein slim patch type was $0.12\;mg/cm^2$ caffein with 2% $Pharmsolv^{\circledR},$ although $1.2\;mg/cm^2$ caffein with 2% $Pharmsolv^{\circledR}$ showed highest amounts permeation, because permeated percentages were significantly lower about $1/4{\sim}1/5$ times.

Keywords

References

  1. J.K. Chen, K. Xu, J.P. Petzer, R. Staal, Y.H. Xu, M. Beistein; P.K. Sonsalla, K. Castagnoli, N. Castagnoli and M.A. Sehwarzschild, Neuroprotection by caffeine and $A_{2A}$ adenosine receptors inactivation in an model of Parkinson's disease, J. Neuroscience, 21, 1-6 RC143 (2001)
  2. G. Potard, C. Laugel, A. Baillet, H. Schaefer and J.P. Marty, Quantitative HPLC analysis of sunscreens and caffeine during in vitro percutaneous penetration studies, Int. J. Pharm., 189, 249-260 (1999) https://doi.org/10.1016/S0378-5173(99)00258-6
  3. F.P. Bonica, V. Carelli, G Di Colo, L. Montenegro and E. Nannipieri, Vehicle effects on in vitro skin permeation of and stratum corneun affinity for model drugs caffeine and testosterone, Int. J. Pharm., 100, 41-47 (1993) https://doi.org/10.1016/0378-5173(93)90073-O
  4. P.A. Daly, D.R. Krieger, A.G Dullo, et al, Ephedrine, caffeine and aspirin: Safety and efficacy for treatment of human obesity. Znt J Obes., 17, S73-S78 (1993)
  5. A. Astrup, S. Toubro, S. Cannon, et al, Caffeine: A double blind, placebo-controlled study of its thermogenic, metabolic and cardiovascular effects in healthy volunteers. Am. J. Clin Nutr., 51, 759-767 (1990) https://doi.org/10.1093/ajcn/51.5.759
  6. A. Astrup and S. Toubro, Thermogenic, metabolic, and cardiovascular responses to ephedrine and caffeine in man. Znt. J. Obes., 17, S41-S43 (1993)
  7. T.J. Horton and C.A. Geissler, Post-prandial thermogenesis with ephedrine, caffeine, and aspirin in lean, pre-disposed obese and obese women. Znt. J. Obes., 20, 91-97 (1996)
  8. 최후균, patch의 개발과 전임상 단계에서의 평가, 제8회 제제기술 워크샵, 한림원, 3-32 (1996)